A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
-
BUSINESS Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
-
BUSINESS Takeda to Realign Japan Sales Team
February 25, 2014
-
BUSINESS Sanofi to Begin Standalone Generic Operation in Japan
February 24, 2014
-
BUSINESS Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
-
BUSINESS MTPC, Daiichi Sankyo Aim to Boost Sales of Struggling Tenelia
February 20, 2014
-
REGULATORY Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
-
REGULATORY Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
-
ACADEMIA Japan Hypertension Society Halts Support for Maker-Linked Seminars, but Gives Leeway for Luncheons
February 18, 2014
-
BUSINESS Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
-
REGULATORY 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
-
BUSINESS Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
-
ACADEMIA University of Tokyo Hospital Allegedly Gave Patient Questionnaire Results on SIGN Trial to Novartis without Consent
February 13, 2014
-
REGULATORY Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
-
ORGANIZATION Prof. Tsuchiya Slams Kowa’s Livalo Trademark Suit
February 10, 2014
-
ACADEMIA University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
-
BUSINESS Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
-
REGULATORY PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
-
BUSINESS Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
-
BUSINESS Teijin Picks Another Pharma Maven for President
February 3, 2014
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…